Glucocorticoid (GC)-Associated Conditions in Patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) with Prolonged Moderate-to-High (M/H) Dose GC Use (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0675; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Background GPA and MPA treatment usually involves rituximab (RTX) or cyclophosphamide (CYC) with GCs...Incidence of GC-associated events during the 12-mo follow-up was compared between pts with M/H dose GC (≥7.5 mg prednisone-equivalent daily dose) during mo 7-9 ( M/H GC 7-9 ) and mo 10-12 ( M/H GC 10-12 ) vs those without...Conclusion M/H GC use was associated with higher rates of GC-associated toxicities during follow-up. Strategies to minimize the need for GC exposure may improve outcomes in pts with GPA or MPA."
Clinical • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Rare Diseases • Vasculitis
|
|
Duvuru Geetha; Kelsey Mirkovic; Phuong Pham; Sam S. Oh; Zachary Wallace; John H. Stone
|